Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes

Critical Reviews in Oncology/Hematology

Volumn 76, Issue 3, 2010, Pages 218-227

  Seymour, John F ^a   Fenaux, Pierre ^b   Silverman, Lewis R ^c   Mufti, Ghulam J ^d   Hellström Lindberg, Eva ^e   Santini, Valeria ^f   List, Alan F ^g   Gore, Steven D ^h   Backstrom, Jay ⁱ   McKenzie, David ⁱ   Beach, C L ⁱ  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b AVICENNE HOSPITAL   (France)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^f CAREGGI UNIVERSITY HOSPITAL   (Italy)

^g H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^h JOHNS HOPKINS UNIVERSITY   (United States)

ⁱ CELGENE CORPORATION   (United States)

Author keywords

Acute myeloid leukemia; AML; Azacitidine; Elderly; Low dose ara C; MDS; Myelodysplastic syndromes; Survival

Indexed keywords

AZACITIDINE; CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; MITOXANTRONE;

AGED; ANEMIA; ASPERGILLOSIS; BLOOD TRANSFUSION; BRONCHITIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DRUG CHOICE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG TOLERABILITY; DYSPNEA; ELDERLY CARE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; GERIATRIC PATIENT; HEART ATRIUM FIBRILLATION; HEART INFARCTION; HEMATEMESIS; HIGH RISK PATIENT; HUMAN; INFECTION; INJECTION SITE BLEEDING; INTERMETHOD COMPARISON; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; OVERALL SURVIVAL; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PNEUMONIA; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT INFECTION; REVIEW; SEPSIS; SEPTIC SHOCK; SURVIVAL TIME; THROMBOCYTOPENIA; URINARY TRACT INFECTION;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; FEMALE; HUMANS; MALE; MYELODYSPLASTIC SYNDROMES;

EID: 77957021267     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.04.005     Document Type: Review

References (25)

1. Nguyen P.L. The myelodysplastic syndromes. Hematol Oncol Clin N Am 2009, 23:675-691.
2. Deschler B., de Witte T., Mertelsmann R., Lubbert M. Treatment decision making for older patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: problems and approaches. Haematologica 2006, 91:1513-1522.
3. Sekeres M.A., Stone R.M., Zahrieh D., et al. Decision-making and quality of life in older adults with acute myeloid leukemia or advanced myelodysplastic syndrome. Leukemia 2004, 18:809-816.
4. Malcovati L., Germing U., Kuendgen A. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
5. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2098.
6. Schuler U. Quality of life in patients with myelodysplastic syndromes. Cancer Treat Rev 2007, 33:S59-S63.
7. Sekeres M.A., Schoonen W.M., Kantarjian H., et al. Characteristics of US patients with myelodysplastic syndromes: results of six cross-sectional physician surveys. J Natl Cancer Inst 2008, 100:1542-1551.
8. Burnett A.K., Milligan D., Prentice A.G., et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndromes in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124.
9. Repetto L., Fratino L., Audisio R.A., et al. Comprehensive geriatric assessment adds information to eastern cooperative oncology group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology study. J Clin Oncol 2002, 20:494-502.
10. Alymara V., Tzouvara E., Vartholomatos G., Chaidos A., Tsiara S., Bourantas K.L. A single-center, retrospective study of management and outcome of 45 elderly AML patients, diagnosed in 2001. J Exp Clin Cancer Res 2004, 23:447-454.
11. Roboz G.J. Arsenic and old lace: novel approaches in elderly patients with acute myeloid leukemia. Semin Hematol 2008, 45(Suppl. 2):S22-S24.
12. Kantarjian H., O'Brien S., Cortes J., et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome. Cancer 2006, 106:1090-1098.
13. Harris N.L., Jaffe E.S., Diebold J., et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. J Clin Oncol 1999, 17:3835-3849.
14. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with conventional care regimens in higher-risk myelodysplastic syndromes: results of a randomised, phase III study. Lancet Oncol 2009, 10:223-232.
15. Cheson B.D., Bennett J.M., Kantarjian H., et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000, 96:3671-3674.
16. Alessandrino E.P., Amadori S., Barosi G., et al. Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology. Haematologica 2002, 87:1286-1306.
17. Aul C., Schneider W. The role of low-dose cytosine arabinoside and aggressive chemotherapy in advanced myelodysplastic syndromes. Cancer 1989, 64:1812-1818.
18. Miller K.B., Kyungmann K., Morrison F.S., et al. The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study. Ann Haematol 1992, 65:162-168.
19. List A.F., Fenaux P., Mufti G., et al. Azacitidine (AZA) extends overall survival in higher risk myelodysplastic syndromes without necessity for complete remission. J Clin Oncol 2008, 26. [Abstract 7006].
20. Vasini G., Malagola M., Piccaluga P.P., Isidori A. Low dose ara-C for myelodysplastic syndromes: is it still a current therapy?. Leuk Lymphoma 2004, 45:1531-1538.
21. Cheson B.D., Jasperse D.M., Simon R., Friedman M.A. A critical appraisal of low-dose cytosine arabinoside in patients with acute non-lymphocytic leukemia and myelodysplastic syndromes. J Clin Oncol 1986, 4:1857-1864.
22. Lyons R.M., Cosgriff T.M., Modi S.S., et al. Hematologic response to three alternative dosing schedules of azacitidine in patients with myelodysplastic syndromes. J Clin Oncol 2009, 27:1850-1856.
23. Silverman L.R., McKenzie D.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
24. Santini V, Fenaux P, Mufti GJ, et al. Management and supportive care measures for adverse events in patients with myelodysplastic syndromes treated with azacitidine. Eur J Haematol pre-published on-line April 12, 2010: doi:10.1111/j.1600-0609.2010.01456.x.
25. Silverman L.R., Demakos E.P., Peterson B.L., et al. Randomized controlled trial of azacitidine in patients with myelodysplastic syndrome: a study of the Cancer and Leukemia Group B. J Clin Oncol 2002, 20:2429-2440.